Halozyme Therapeutics Raises 2026 Revenue Outlook and Boosts Buybacks

EarningsCorporate Action
โดย Simply Wall St·US·Read original
Summary · why it matters

Halozyme Therapeutics raised its full-year 2026 revenue guidance to a range of US$1.84 billion to US$1.91 billion after reporting record second-quarter revenue of US$481 million and net income of US$229.91 million. The company also accelerated capital returns by completing US$750 million of share repurchases under a 2024 authorization and buying an additional US$175.01 million of stock under a new 2026 program, while signing five new ENHANZE-related collaboration deals that broaden its royalty base.

Impact on stocks 1

Biotech & Genomic Medicine▲ · 1 stocks
Halozyme Therapeutics Inc
HALO
▲ PositiveCapitalDemandrelevance

Raises 2026 revenue guidance, reports record Q2 revenue/net income, and boosts buybacks.

© 2026 MarketDXNews